Related Experiment Video
Updated: Jan 20, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes
Alexandre Jehl1,2,3, Christine Cugnet-Anceau1,2,3,4, Corinne Vigouroux1,5,6
1French Network of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS) and FIRENDO Network, Paris and Lyon, France.
Objective:
Anti-programmed cell death-1 (anti-PD-1) antibodies have revolutionized advanced cancer therapy. Anti-PD-1 therapy is responsible for immune-related adverse events, with frequent endocrine manifestations, including acute-onset type 1 diabetes. Acquired generalized lipodystrophy (AGL) is a rare disease, believed to be immune mediated, characterized by loss of adipose tissue and insulin resistance-associated complications.
Research Design And Methods:
We describe the first reported case of AGL induced by immune checkpoint therapy.
Results:
A 62-year-old woman with metastatic melanoma treated with nivolumab was referred for major hyperglycemia, hypertriglyceridemia, and nonalcoholic steatohepatitis. She had presented with a rapidly progressive generalized loss of subcutaneous adipose tissue. Diabetes was associated with severe insulin resistance and undetectable plasma leptin. Subcutaneous biopsy revealed atrophic adipose tissue infiltrated with cytotoxic CD8+ T lymphocytes and fibrosis.
Conclusions:
AGL is an additional immune-related adverse event of anti-PD-1 therapy that leads to severe insulin resistance-associated complications.
Insights
Immune checkpoint therapy, specifically anti-PD-1 antibodies, can cause acquired generalized lipodystrophy (AGL). This rare condition leads to severe insulin resistance and related complications.
Area of Science:
- Immunology
- Endocrinology
- Oncology
Background:
- Anti-programmed cell death-1 (anti-PD-1) antibodies are a revolutionary cancer therapy.
- These therapies can cause immune-related adverse events, including endocrine disorders like type 1 diabetes.
- Acquired generalized lipodystrophy (AGL) is a rare, immune-mediated condition causing adipose tissue loss and insulin resistance.
Observation:
- A patient with metastatic melanoma treated with nivolumab developed AGL.
- The patient presented with hyperglycemia, hypertriglyceridemia, nonalcoholic steatohepatitis, and rapid loss of subcutaneous adipose tissue.
- Biopsy showed adipose tissue with CD8+ T cell infiltration and fibrosis.
Findings:
- This case represents the first report of AGL induced by immune checkpoint therapy.
- The patient experienced severe insulin resistance and undetectable leptin levels.
- The findings link AGL to anti-PD-1 therapy.
Implications:
- AGL is a newly identified immune-related adverse event associated with anti-PD-1 therapy.
- This condition can lead to significant insulin resistance and associated complications.
- Awareness of AGL is crucial for managing patients undergoing immune checkpoint therapy.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Generalized Hooke's Law
Generalized Anxiety Disorder
Social Foundations of Self II: The Generalized Other
Generalization, Discrimination, and Extinction
Generalization occurs when a behavior reinforced in one context is performed in similar situations. For instance, a student who studies diligently for calculus and receives excellent grades might apply the same study habits to psychology and history, expecting similar results. Generalization shows how learning in one setting can influence behavior in...
PD Controller: Design
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
What is the Immune System?